digest
Short Summary
Main recommendation: Proceed cautiously with methylene blue, and only in controlled, medically supervised settings, because it can help with mitochondrial electron balance but can also cause serotonin syndrome and reductive stress at high doses. Both speakers say they do not currently take it or use it with patients, and Dr. Palmer cites small, not well-designed pilot trials as the main evidence.
Key Points
- Methylene blue acts as an electron shuttle, able to both accept and donate electrons, which is why it is studied as a mitochondrial agent.
- The rationale is that electrons leaking from dysfunctional mitochondria create reactive oxygen species (oxidative stress), which Dr. Palmer says decades of evidence link to aging, neurodegeneration, obesity, type 2 diabetes, and neuropsychiatric disorders.
- Balance matters: too little or too much electron flow is harmful, and too much methylene blue could shift tissue toward reductive stress, which has been found in schizophrenia and bipolar disorder.
- Evidence is limited to small, not very well designed pilot trials across depression, bipolar disorder, schizophrenia, and Alzheimer's disease, many suggesting benefit.
- Because methylene blue can affect MAO activity and serotonin levels, the speakers are cautious about using it.
Details Worth Noting
- Concrete instructions: The transcript gives no dosing, frequency, timing, or preparation details, and the speakers say they do not know the dose range. The only actionable advice is to obtain methylene blue only from a very reputable source, to consume it in a way that makes sense, and to be alert to serotonin syndrome, which may present as anxiety, panic, nausea, jitteriness, or fever, and can be fatal in extreme cases.
- Serotonin syndrome is often misattributed to psychiatric symptoms, especially in people taking SSRIs, so new anxiety, nausea, or feeling "not right" should not be automatically dismissed.
- Methylene blue can stain teeth, the tongue, and urine blue. Intravenous infusions are described as a medically approved treatment that can be done safely.
- The speakers note methylene blue is off patent, so there is little commercial incentive for large, well-designed trials.
- Huberman cites a recent Stanford mouse study suggesting serotonin drops as dopamine rises, and says this serotonin drop may be as important as the dopamine rise for reinforcement, which is one reason he is reluctant to raise serotonin pharmacologically.
Bottom Line
Methylene blue is a promising but under-tested mitochondrial agent with real safety risks, so any use should be medically supervised, sourced reputably, and watched closely for serotonin syndrome.
